Chemistry:AL-38022A

From HandWiki

AL-38022A is a serotonin receptor agonist and psychedelic drug of the indazolethylamine family related to the psychedelic tryptamine 5-MeO-AMT.[1] It is one of a range of similar drugs developed for scientific research and with some possible clinical applications such as in the treatment of glaucoma.[1][2][3] The drug acts as a potent and selective agonist for the 5-HT2 family of serotonin receptors, with highest binding affinity for the 5-HT2C subtype and around four times less affinity for 5-HT2A and 5-HT2B.[1][2][4] In drug discrimination tests in animals, it fully substituted for the psychedelic drugs 5-MeO-DMT and DOM.[1][4] AL-38022A was first described in the scientific literature by Richard Glennon and colleagues in 2009.[4]

See also

References

  1. 1.0 1.1 1.2 1.3 "Chemistry and Structure-Activity Relationships of Psychedelics". Curr Top Behav Neurosci 36: 1–43. 2018. doi:10.1007/7854_2017_475. PMID 28401524. "A variation on ring-substitution patterns was the discovery of indazole ligands with potent 5-HT2A agonist activity (May et al. 2003a, 2006). For example, AL-38022A 15 was developed as a highly potent 5-HT2A agonist that had efficacy in reducing intraocular pressure in glaucoma. Compound 15 was a full agonist at all three 5-HT2 family receptors, with EC50 values between 0.5 and 2.2 nM for several functional responses (May et al. 2009). In a drug discrimination assay in rats trained to discriminate the hallucinogen DOM from saline, 15 produced full substitution, with an ED50 of 0.05 mg/kg. Similarly, it produced full substitution in monkeys trained to discriminate DOM from saline, with an ED50 of 0.04 mg/kg, comparable to the potent 5-HT2A/2C agonist DOI.". 
  2. 2.0 2.1 "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev 124 (1): 124–163. January 2024. doi:10.1021/acs.chemrev.3c00375. PMID 38033123. "Later, May et al. also reported compound AL-38022A (30), which has the same benzopyrazole scaffold and an additional pyran ring fused to the bicyclic core, as a high affinity (Ki = 0.13 nM, [ 125I]-DOI) and potent agonist (EC50 = 22.5 nM, Emax = 87%) at the r5-HT2AR.141 Compound AL-38022A also exhibited high selectivity for 5-HT2 receptors against other related receptors.141". 
  3. Chen HH, May JA, Severns BS. Pyranoindazoles and their use for the treatment of glaucoma. US 6881749
  4. 4.0 4.1 4.2 "Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-gindazol-1-yl)-1-methylethylamine]"]. Pharmacology, Biochemistry, and Behavior 91 (3): 307–314. January 2009. doi:10.1016/j.pbb.2008.07.015. PMID 18718483.